A Phase 3 interventional study of Intrarosa and Placebos in Menopause, Genitourinary Syndrome of Menopause and Vulvovaginal Atrophy, sponsored by Center for Vulvovaginal Disorders. Status unknown at 2 sites in United States. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-31.
Sponsored by Center for Vulvovaginal Disorders · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.
Among the 56 studies in Dyspareunia with a site in United States, this one is the 34th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 3, and was the 39th registered.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
Browse Dyspareunia studies →8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40–90 · Women only · Healthy volunteers
Azure Biotech Inc. · Sites in United States
Ages 45–60 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 40 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 127 interventional studies indexed under Dyspareunia.
Median enrollment 60 across the 53 interventional studies, 200 across the 3 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
Center for Vulvovaginal Disorders is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Center for Vulvovaginal Disorders has 1 study filed under Dyspareunia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyspareunia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197568Azure Biotech Inc.Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | 2026-12-31 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Dyspareunia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tissues of the genitals of women are both androgen (testosterone) and estrogen dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor all depend on androgens for normal function. In addition, the glands, which secrete lubrication during sexual arousal, also require androgens to function. Deficiencies of both estrogens and androgens occur naturally during menopause. Menopause-related deficiencies of these hormones lead to thinning in the tissues of the genital and urinary systems which have been termed Genitourinary Syndrome of Menopause (GSM). Patients with GSM will frequently complain of dryness and/or pain during sexual intercourse.
Historically, GSM treatment involved both androgens and estrogens, However, over the past few decades estrogen based therapies have become much more common. More recently, clinical trials have demonstrated that local vaginal dehydroepiandrosterone (Intrarosa®) improves symptoms in menopausal women who have moderate to severe pain with intercourse.
Intrarosa® vaginal inserts are a prescription medicine approved by the U.S. Food and Drug Administration (FDA) used in women after menopause to treat moderate to severe pain during sexual intercourse caused by changes in and around the vagina that happen with menopause.
Tissues in the genitourinary system are both androgen- and estrogen-dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor are androgen-responsive. In addition, the minor vestibular glands and the major vestibular glands (Bartholin's and Skene's) are androgen-dependent, mucin-secreting glands. Deficiencies of both estrogens and androgens can occur both naturally during menopause or iatrogenically because of certain medications (e.g. Depo Lupron, spironolactone) or surgically (oophorectomy). Menopause-related deficiencies of these sex hormones lead to atrophic changes in the genitourinary system which have been termed genitourinary syndrome of menopause (GSM).
While erythema is a nonspecific finding in atrophic tissue, focal painful erythema in the androgen-dependent vestibule, particularly near the ostia of the Bartholin's glands (4:00 and 8:00 o'clock) and Skene's glands (1:00 and 11:00 o'clock) or lesser vestibular glands, is highly suggestive of GSM. Patients with GSM will frequently complain of penetrative dyspareunia and experience allodynia with the cotton swab palpation of the vulvar vestibule. During examination of the vulvar vestibule, the examiner might note general pallor with superimposed erythema. Physical exam can be improved by magnification (i.e. vulvoscopy).
Historically, GSM treatment involved both androgens and estrogens. However, in the absence of information about intracrinology, over the past few decades, estradiol-based therapies have been used exclusively. More recently, double-blind, placebo controlled clinical trials demonstrated that local vaginal dehydroepiandrosterone (Intrarosa®) improves symptoms in postmenopausal women including moderate to severe dyspareunia. These trials have demonstrated improvement in both subjective measures (such as improvement in dyspareunia) as well as objective measurement of vaginal health (improved vaginal maturation index, decreased vaginal pH) but they have not attempted to demonstrate improvement in the health of the vulvar tissue.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
Drug: Intrarosa
Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
Drug: Placebos
Prasterone intravaginal inserts
Also known as: prasterone, Dehydroepiandrosterone, DHEA
Placebo intravaginal inserts
Changes from baseline in morphological content of vulvar and vaginal cells
Changes from baseline in density of androgen, estrogen and progesterone receptors. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in morphological content of vulvar and vaginal cells
Changes from baseline in tissue steroid concentrations. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in morphological content of vulvar and vaginal cells
Changes from baseline in blood steroid concentration. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in protein content of vulvar and vaginal cells
Changes from baseline in mucin. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in enzymatic content of vulvar and vaginal cells
Changes from baseline in enzymatic content (HSD17B5, HSD3B1, 5alphaRED2, aromatase, HDS17B1, sulfotransferase 2A1, sulfatase and UGT2B). All enzymes have the same unit of measure. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in antigen content of vulvar and vaginal cells
Changes from baseline in PGP9.5. Unit of measure to be determined.
Time frame: 2 years
Changes from baseline in antigen content of vulvar and vaginal cells
Changes from baseline in Ki-67 antigen. Unit of measure to be determined.
Time frame: 2 years
Mean change from baseline in subject's scores on pain severity subscale VPAQ
The Vulvar Pain Assessment Questionnaire (VPAQ) was developed to assess the dimensions of the pain experience in studies of chronic pain. It consists of 6 primary (pain severity, emotional response, cognitive response, and interference with life, sexual function, and self-stimulation/penetration) and 3 supplementary subscales (pain quality, coping skills, and partner factors). The pain severity subscale of the VPAQ consists of 3 pairs of verbal rating scale that test both pain intensity and pain affect. Each verbal rating scale is a 5-point scale with the following options: none=0, mild=1, moderate=2, severe=3, and worst possible=4. The calculated mean produces the overall score for the pain severity subscale ranging from 0-4 (4 is the worst score).
Time frame: 2 years
Plan to share: No
Start is estimated for Mar 2019; primary completion for Jan 2021, 22 months later.
Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's planned 22 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dehydroepiandrosterone
Center for Vulvovaginal Disorders